Latest Content

Depending on dose, firmonertinib shrank tumors in 43% to 68% of patients as a first treatment for EGFR PACC-mutant lung cancer in the phase 1b FURTHER trial.

Debbie Legault, whose daughter was diagnosed with breast cancer at 27, urges shoppers to skip pink ribbon products and donate directly to support organizations.

A study of 52,236 patients with cancer found that episodes of unintended weight loss affected 46.63% of patients and were tied to shorter overall survival.

Diagnosed with leukemia at 8 years old, Harper feared that losing her hair would change who she was. She reflects on body image, confidence and finding a sense of herself during cancer treatment.

A psycho-oncologist answers 5 common questions about cancer-related anxiety, depression, fear of recurrence and emotional well-being.

U.S. counties where more residents had medical debt in collections had higher rates of late-stage lung, head and neck, colorectal and several other cancers, according to a study of 2,958 counties published in October 2026 in JAMA Network Open.

Diagnosed with stage 4 breast cancer weeks after giving birth, Eileen Carter explains why getting a second opinion changed the course of her care.

Libtayo survival data, a rare positive osteosarcoma trial and new ADCs for breast, lung and stomach cancers are among ESMO 2026 abstracts to watch.

Diagnosed with bone cancer at 14, college setter Gabby Orlet shares how volleyball, honesty and her family carried her through years of treatment.

Since September 2024, every U.S. mammogram report must tell patients whether their breast tissue is dense. Here is what that notice means, why it matters and what to ask your care team.

Noah Elliott, now a Paralympic snowboarder, counted small wins during inpatient chemotherapy and found inspiration in the youngest children on his hospital floor.

Diagnosed with stage 4 breast cancer weeks after giving birth, Eileen Carter and her chaplain husband share why a second opinion changed everything.

Five colorectal cancer trials recently began treating patients, testing targeted drugs, bispecific antibodies and immunotherapy. Here’s what each one is studying.